Hepatitis C Articles (HCV)
Back
 
Zepatier
EFFICACY AND SAFETY OF GRAZOPREVIR/ELBASVIR +/- RBV FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV G1, G4 OR G6 INFECTION WHO PREVIOUSLY FAILED PEGINTERFERON/RBV: C-EDGE TREATMENT-EXPERIENCED
- (04/23/15)
AASLD:
The Combination of Elbasvir and Grazoprevir ± RBV Is Highly Effective for the Treatment of GT1a-Infected Patients
- (11/17/15)
hepDART:
Optimizing Outcomes in HCV Patients: Elbasvir/Grazoprevir: kidney disease/IDUs/resistance
(01/04/16)
AASLD:
AN INTEGRATED ANALYSIS OF 402 COMPENSATED CIRRHOTIC PATIENTS WITH HCV GENOTYPE (GT) 1, 4 or 6 INFECTION TREATED WITH Elbasvir/GRAZOPREVIR
- (11/19/15)
AASLD:
Prevalence and Impact of Baseline NS5A Resistance-Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1a Infection - 16 Weeks vs 12 weeks
- (11/23/15)
C-EDGE COINFECTION: PHASE 3 STUDY OF GRAZOPREVIR/ELBASVIR IN PATIENTS WITH HCV/HIV
- (04/23/15)
View Older Articles
Back to Top
www.natap.org